The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

Monitoring absolute neutrophil count levels beyond 2 years of clozapine treatment is no longer necessary, new international ...

The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...

The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.

We take no position on the wisdom or folly of West Virginia’s abortion law," Judge J. Harvie Wilkinson III wrote for the 2-1 ...

A recent appellate decision that allowed West Virginia to block access to the abortion-inducing drug mifepristone is fueling ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...